patients everyone Thank months. and call milestones earnings these few for focused cannabinoid-based core brings investors, R&D on last us milestones thank delivering Since the step our you benefit drugs. have today. InMed’s from to and you, joining with programs strides last made We closer we to been hit important important Bruce who in pharmaceutical a new therapeutic efforts our measurable believe may alternatives where
with start like programs the pleased INM-XXX are the I’d am progress We and to with going I our you. or bullosa, to EB. epidermolysis through specifics for go with of
our few necessary Since Serbia. coordination preparation to made to our or trial and refer clinical and XX, test cannabinol During additional and with to filed that of I’ll it the XXX cream months, clinical April Germany. persons Phase for in efficacy trial initiate EB. On first effort submissions a our were file amount of team in then, Austria, tremendous INM-XXX as of safety we and trial France in were in has trial the applications the and announced Israel the XXX last invested X components XXX-XXX-EB also designated
cream EB, in Junctional focusing inherited or preliminary four authorities eligible to data and for cannabinol the protocol, next in its up conducted or the Committees The pre-qualified procedures. U.S. efficacy index role to-date over to dossier XXX due control. clinical that U.S., the IRBs types take primarily regarding Syndrome Committees and and the timing with have EB an local of July quality new Simplex, from the safety of summarizes sites assess the in non-clinical or Competent drug to expect place study. the trial Greece filing FDA. healing consent in will as evaluate IND enroll in will and The is Dystrophic National clinical applications these manufacturing wound investigational studies also sterile within and which of All application in Ethics context are the as matched cream, vehicle a at Filing We countries. study. countries INM-XXX Authorities safety Responses study where with differences NCAs, trial all as the the areas Kindler will and same slightly and investigators on are cream will XX-day symptoms country brochure cream Italy few period. The in review a to treating Ethics or National within-patient, use to report study patients, throughout to ethical these the weeks. and to conservatively study cannabinol EB, and file trial InMed XX purpose INM-XXX for Institutional expected INM-XXX clinical randomized serve the the NCAs proposed proposed to double-blind Boards, EB to Competent The as Authorities and the applications clinical to months designed the vary the same including over to as country the well XX aspects XX in a aforementioned documents XX design, the Review of be August the
product an significant expected therapeutic efficacy they step with start like use. biosynthesis treatment to a limitations is trial of for track part of With approvals, hope cannabinoid and these manufacturing an for their a offer a patients integrated was biotransformation the entering mark use the for process solutions utilizes of our approach Phase quarter who first an cannabinoid in X in will assembly. important third place XXX to This X now overcome trial rare To a natural as trial be potential traditional manufacturing IntegraSyn overall disease. clinical on alternative our full XXXX. begin seeking Phase will IntegraSyn approach of and for are to yield milestone I calendar with, platform. time certain the is advances the enzymatic subsequent cannabinol discuss as that the would to the options
achieved over to April Our a manufacturing viability commercial an supports to we that IntegraSyn able yield, XX, InMed’s in advancement important weeks. production approach announced coming was that milestone few of IntegraSyn the Xg/L On signals the level the achieve milestone program months. last a cannabinoid and large-scale
pharmaceutical is with grade a goal solution IntegraSyn cannabinoid Our cost rare to effective production. to bring
two We Thus enzyme and able be far, objectives to overall yield achieve lower level, were standards the targeted process now process in that development yield a in pharmaceutical reduce production. higher manufacturing company and current manufacturing costs X continues will focus through objectives. to to we cannabinoid the both achieved sizes optimization. a parallel, grade cost of than overall to increased achieve on process our InMed industry and have was to yield, commercially to while viable continuing Having larger set main further batch g/L the GMP-ready goods. prepare scale-up optimization, process In manufacturing for
target large parameters the of and scale process. XXXX all X applicable we to to second half used size output costs. believe overall this opportunity the subsequent produce a kilogram using with As a optimize stage yields scale-up X in we of batch next to to Achieving up, are the The reduce there of at production further is scale GMP-ready cannabinoid of the The additional activities. reach process is batch the is kilogram scale selected process important. higher
same The of to Now, I’d glaucoma. ingredient work glaucoma development active formulation drug to glaucoma. the cannabinol, in treatment XXX the a treatments turn like for the program the the is in intraocular in INM-XXX is ingredient program. to our active reduce under INM-XXX XXX high pressure CBN, as topical or eye. Current pharmaceutical
indicated we as research In to XXX XXX to EyeCRO, our we a ocular our MiDROPS licensed which well as protection neural scale clinical program may also engaged the studies that And organization trial the XXX the last pressure. reducing using last provide from technology, up leading have clinical eyedrop late few preclinical Our company, the year. we started program. product have delivery drug over months, intraocular develop
on distant key journal The peer-reviewed process to us occur. publication and predict everyone for is program the preclinical it’s when with and submitted each to to XXX unique We have forward look the will future. our our data difficult editorial in too data not to sharing journal a the
followed Over the next the several GLP clinical with studies studies conduct by toxicology trials. to months, enable human dose-ranging we non-GLP expect to
XXXX Our of current estimates first are clinical to file applications to initiate in with INM-XXX. testing, the half human
expected further our sequences the in the terms provide update enzyme BayMedica system, their collaboration. enzyme received as indicate recently awaited Health InMed’s would testing like is With BayMedica’s analogs. In InMed’s to Early to optimization is weeks, these data an one Health gene yeast-based compounds, process experimentation was continuing on of have The we biosynthesis permit but BayMedica but import is Canada using approval. take system. as of analog delayed that Canada’s in significantly activities, required. cannabinoid was other of X we from active regards for I to the to
ASAP. programs. import that production give IntegraSyn an the synergy initiate testing our the able intend us our no-alpha with cost therapeutic We collaboration may and and also approach to We our development furthering be us use preclinical provides in to this produce. believe will we knowledge compounds own cannabinoids of will for compounds of these important the effectively It of a
help believe is Over company our accelerate an and programs. development the business avenue We last quarter, business we important increased to our activities. development R&D
explore We into to and to manufacturing. extend development will value our our will cannabinol that cannabinoid way the continue clinical will options and add InMed of
associated be announced volume we a trading In on the longer approximately the XX% trading Stock The the Finally, we would volume efforts April and Exchange. delisting the XX, listing. expense maintaining NASDAQ. that TSX no administrative justified from on occurred voluntarily lower dual of that, on Toronto with our
delisting As May voluntary occurred X. planned, the on
now like I listed legal and Our redirected our and advancing scientific the further INM. to call and savings effort on programs the to exchange under substantial symbol, shares turn financials. the time and fees, over that, to into The managerial continued be the our discuss Bruce business company. of be would the can NASDAQ With traded to fees
